Before today’s planned blog post, I wanted to mention a good NY Times article which highlights how long the virus which causes COVID-19 can be present on surfaces:
Full link from NY Times: How Long Will Coronavirus Live on Surfaces or in the Air Around You?
The virus lives longest on plastic and steel, surviving for up to 72 hours. But the amount of viable virus decreases sharply over this time. It also does poorly on copper and cardboard, surviving four to eight hours; the latter finding suggests packages that arrive in the mail should be safe — unless the delivery person has coughed or sneezed on it or has handled it with contaminated hands.
That the virus can survive and stay infectious in aerosols is also important for health care workers.
For weeks experts have maintained that the virus is not airborne. But in fact, it can travel through the air and stay suspended for that period of about a half-hour.
The virus does not linger in the air at high enough levels to be a risk to most people who are not physically near an infected person. But the procedures health care workers use to care for infected patients are likely to generate aerosols.
The original article from NEJM: Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
This “C” virus was hard to cure until recently. More good news from recently published studies for pediatric hepatitis c virus (HCV) treatment:
- KB Schwarz et al. Hepatology 2020; 71: 422-30.
- MM Jonas et al. Hepatology 2020; 71: 456-62.
- AASLD-IDSA Practice Guidance Panel. Hepatology 2020; 71: 686-721
In the first study of an all oral regimen of ledipasvir-sofosbuvir, sustained virological response at 12 weeks after dosing (SVR12) was achieved in 33 of 34 (97%) of children 3-<6 yrs of age with genotypes 1 or 4 (only 1 with type 4). No serious adverse effects were reported. Dosing: 33.75 mg/150 mg if <17 kg or 45 mg/200 mg if ≥17 kg. The one non-responder discontinued treatment due to drug taste. Pharmokinetic studies in 13 patients confirmed appropriate medication dosing.
In the second study of glecaprevir/pibrentasvir (G/P), as part of the DORA phase 2/3 nonrandomized, open-label trial, adolescents 12-17 received the ‘adult’ regimen of 300 mg/120 mg daily for 8-12 weeks in accordance with indication duration based on adult data. Among the 47 patients (genotypes 1, 2, 3, 4), 100% achieved SVR12. Safety profile was consistent with prior studies in adults.
The third publication, which is quite lengthy, highlights updated recommendations for HCV in adults and children (this will be reviewed in tomorrow’s post).
Related blog posts:
- HCV Guidelines This website links to AASLD-IDSA website. Of note, updated recommendations (November 2019) for children are summarized here: HCV in Children
- Opioid Epidemic Affecting Adolescent Hepatitis C Infections
- Heroin Epidemic Causing Surge in Hepatitis C Infections
- HCV now more deadly than HIV
- Wiping out Hepatitis C